Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NNVC
stocks logo

NNVC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for NanoViricides, Inc (NNVC.A) is -2.30, compared to its 5-year average forward P/E of -2.70. For a more detailed relative valuation and DCF analysis to assess NanoViricides, Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.70
Current PE
-2.30
Overvalued PE
-1.26
Undervalued PE
-4.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-4.19
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
8.05
Undervalued EV/EBITDA
-16.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.51
Current PS
0.00
Overvalued PS
1.98
Undervalued PS
-0.96
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NNVC News & Events

Events Timeline

(ET)
2025-12-01
08:50:00
NanoViricides Signs Master Services Agreement with Only Orphans Cote for Orphan Drug Strategy
select
2025-11-17 (ET)
2025-11-17
08:54:23
NanoViricides Announces Q3 Earnings Per Share of 10 Cents Compared to 23 Cents Last Year
select
2025-11-11 (ET)
2025-11-11
08:40:59
NanoViricides offers 3.57 million shares at $1.68 in a registered direct sale.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
05-16Yahoo Finance
NanoViricides: Fiscal Q3 Earnings Snapshot

  • Company Financial Performance: NanoViricides Inc. reported a loss of $2.2 million in its fiscal third quarter, equating to a loss of 14 cents per share.

  • Location and Reporting Source: The company is based in Shelton, Connecticut, and the information was generated by Automated Insights using data from Zacks Investment Research.

[object Object]
Preview
9.0
03-07Business Insider
Biotech Alert: Searches spiking for these stocks today

  • Surge in Biotech Stock Interest: Several biotech companies, including NanoViricides and Tenaya Therapeutics, are experiencing significant increases in search activity, indicating heightened investor interest in their innovative therapies and clinical developments.

  • Key Developments in Clinical Trials: Companies like GeoVax Labs and Tonix Pharmaceuticals are advancing their clinical programs, with promising results in vaccine development and pain management therapies, while others like Editas Medicine and TC Biopharm are making strategic moves to enhance their market positions.

[object Object]
Preview
4.0
2024-08-25SeekingAlpha
Earnings week ahead: NVIDIA, CrowdStrike, Salesforce, Lululemon and more (NASDAQ:NVDA)

  • Upcoming Earnings Reports: Several high-profile companies, including NVIDIA, Salesforce, and Lululemon, are set to report their quarterly earnings next week, with analysts closely monitoring their performance for insights into the tech and retail sectors.

  • Analyst Sentiment: While some companies like NVIDIA and Salesforce have positive outlooks from analysts, others like Nordstrom and Lululemon face mixed reviews due to operational challenges and market conditions, impacting their stock ratings.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is NanoViricides, Inc (NNVC) stock price today?

The current price of NNVC is 1.22 USD — it has increased 9.91 % in the last trading day.

arrow icon

What is NanoViricides, Inc (NNVC)'s business?

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.

arrow icon

What is the price predicton of NNVC Stock?

Wall Street analysts forecast NNVC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for NNVC is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is NanoViricides, Inc (NNVC)'s revenue for the last quarter?

NanoViricides, Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is NanoViricides, Inc (NNVC)'s earnings per share (EPS) for the last quarter?

NanoViricides, Inc. EPS for the last quarter amounts to -0.10 USD, decreased -56.52 % YoY.

arrow icon

What changes have occurred in the market's expectations for NanoViricides, Inc (NNVC)'s fundamentals?

The market is revising No Change the revenue expectations for NNVC for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -18.12%.
arrow icon

How many employees does NanoViricides, Inc (NNVC). have?

NanoViricides, Inc (NNVC) has 7 emplpoyees as of December 05 2025.

arrow icon

What is NanoViricides, Inc (NNVC) market cap?

Today NNVC has the market capitalization of 21.78M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free